Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial...
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares...
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company...
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company...
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash...
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.